Company: MLTX
Filing Date: 2025-08-05
Form Type: 10-Q
Source: 0001821586-25-000018
Chunk: 3

Company: MoonLake Immunotherapeutics
Filing Date: 2025-08-05
Form: 10-Q
Item: Part I, Item 1
Chunk 3
---
 $1,828 Other comprehensive loss— $— — $— $— $— $564 $564 $12 $576 Net loss for the three months ended June 30, 2024— $— — $— $— $(24,267)$— $(24,267)$(492)$(24,759)Balance at June 30, 202462,874,637 $6 995,267 $— $671,998 $(154,597)$3,256 $520,663 $9,368 $530,031 

The accompanying Notes are an integral part of these Unaudited Condensed Consolidated Financial Statements.

4

MOONLAKE IMMUNOTHERAPEUTICSCONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY(Unaudited)

Class A Ordinary SharesClass C Ordinary SharesAdditional Paid-In CapitalAccumulated DeficitAccumulated Other Comprehensive IncomeTotal Shareholders' EquityNoncontrolling InterestsTotal Equity(in thousands except share data)SharesAmountSharesAmountBalance at January  1, 202563,077,431 $6 841,269 $— $677,415 $(235,593)$4,997 $446,825 $6,566 $453,391 Share-based compensation under the ESPP and Equity Incentive Plan— — — — 2,279 — — 2,279 11 2,290 Conversion of MoonLake Class C Ordinary Shares into Class A Ordinary Shares111,949 — (111,949)— 841 — 10 851 (851)— Options exercised and converted under the Employee Stock Option Plan, net of stamp duty fee93,347 — — — 129 — — 129 (9)120 Issuance of Restricted Stock Awards under the Equity Incentive Plan191,526 — — — — — — — — — Net loss for the three months ended March 31, 2025— — — — — (39,944)— (39,944)(615)(40,559)Other comprehensive loss— — — — — — (2,620)(2,620)(41)(2,661)Balance at